Eosinophilic Granulomatosis with Polyangiitis Presenting with Central Retinal Artery Occlusion During Treatment with Anti-interleukin-5 Receptor Monoclonal Antibody

被引：0

作者：

Nishiyama, Hirono ^{[1
]}

Tajiri, Tomoko ^{[1
]}

Yamabe, Toru ^{[1
]}

Yasukawa, Tsutomu ^{[2
]}

Takeda, Norihisa ^{[1
]}

Fukumitsu, Kensuke ^{[1
]}

Fukuda, Satoshi ^{[1
]}

Kanemitsu, Yoshihiro ^{[1
]}

Uemura, Takehiro ^{[1
]}

Ohkubo, Hirotsugu ^{[1
]}

Takemura, Masaya ^{[1
]}

Maeno, Ken ^{[1
]}

Ito, Yutaka ^{[1
]}

Oguri, Tetsuya ^{[1
]}

Naniwa, Taio ^{[1
]}

Niimi, Akio ^{[1
]}

机构：

[1] Nagoya City Univ, Grad Sch Med Sci, Dept Resp Med Allergy & Clin Immunol, Nagoya, Aichi, Japan

[2] Nagoya City Univ, Grad Sch Med Sci, Dept Ophthalmol & Visual Sci, Nagoya, Aichi, Japan

来源：

INTERNAL MEDICINE | 2021年 / 60卷 / 22期

关键词：

eosinophilic granulomatosis with polyangiitis; central retinal artery occlusion; anti-neutrophil cytoplasmic antibody; asthma; eosinophilia; CHURG-STRAUSS-SYNDROME;

D O I：

10.2169/internalmedicine.7027-21

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Eosinophilic granulomatosis with polyangiitis (EGPA) is an anti-neutrophilic cytoplasm antibody (ANCA)-associated vasculitis characterized by asthma and eosinophilia. Although EGPA involves multiple organs, ocular involvement is infrequent and often carries a poor visual prognosis. We herein report a rare case of EGPA presenting with central retinal artery occlusion (CRAO) in which visual loss developed during treatment with anti-interleukin (IL)-5 receptor monoclonal antibody, and improvement in visual outcomes was attained after treatment combining high-dose oral corticosteroids, cyclophosphamide and an anticoagulant. Physicians should consider CRAO as an ophthalmic manifestation of EGPA in patients with severe eosinophilic asthma.

引用

页码：3631 / 3634

页数：4

共 50 条

[21] Review of Three New Anti-interleukin-5 Monoclonal Antibody Therapies for Severe Asthma
Agumadu, Vivian C.
Ramphul, Kamleshun
Mejias, Stephanie G.
Sonaye, Ruhi
Sombans, Shaheen
Lohana, Petras
CUREUS, 2018, 10 (08):
[22] Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma
Hilvering, Bart
Xue, Luzheng
Pavord, Ian D.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2015, 9 (04) : 135 - 145
[23] Treatment for severe eosinophilic asthma-consistent effect of anti-interleukin-5 antibodies?
Castro, Mario
Bacharier, Leonard B.
LANCET, 2016, 388 (10056): : 2059 - 2060
[24] Anti-IgE monoclonal antibody (omalizumab) in refractory and relapsing eosinophilic granulomatosis with polyangiitis: data from 17 patients
Jachiet, M.
Samson, M.
Cottin, V.
Kahn, J.
Le Guenno, G.
Le Jeunne, C.
Mouthon, L.
Guillevin, L.
Terrier, B.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (09) : S163 - S163
[25] Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions
Büttner, C
Lun, A
Splettstoesser, T
Kunkel, G
Renz, H
EUROPEAN RESPIRATORY JOURNAL, 2003, 21 (05) : 799 - 803
[26] Successful treatment of eosinophilic fasciitis with the anti-IL5 receptor monoclonal antibody benralizumab
Rizzo, C.
La Barbera, L.
Camarda, F.
Castaniti, G. M. Destro
Orlando, E.
Guggino, G.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2023, 41 (03) : 763 - 764
[27] The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: Asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis
Nagase, Hiroyuki
Ueki, Shigeharu
Fujieda, Shigeharu
ALLERGOLOGY INTERNATIONAL, 2020, 69 (02) : 178 - 186
[28] Development of Rheumatoid Arthritis During Anti-Interleukin-5 Therapy in a Patient with Refractory Chronic Eosinophilic Pneumonia
Kawabata, Hiroki
Satoh, Minoru
Yatera, Kazuhiro
JOURNAL OF ASTHMA AND ALLERGY, 2021, 14 : 1425 - 1430
[29] Effects of mepolizumab, an anti-interleukin-5 monoclonal antibody, on blood eosinaphil counts in patients with hypereosinophilic syndrome
Weller, P. E.
Gleich, G. J.
Busse, W. W.
Rothenberg, M. E.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 119 (01) : S209 - S209
[30] Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial
Straumann, A.
Conus, S.
Grzonka, P.
Kita, H.
Kephart, G.
Bussmann, C.
Beglinger, C.
Smith, D. A.
Patel, J.
Byrne, M.
Simon, H-U
GUT, 2010, 59 (01) : 21 - 30

← 1 2 3 4 5 →